Amantadine

Limits on what this shows

• Key negative/null findings: No human peripheral-tissue (platelet, lymphocyte, muscle) or CNS mitochondrial-function study using amantadine was located after a genuinely broad, multiply-phrased search; all three primary sources are cell or animal models of acute or viral injury, not of routine Parkinson's disease treatment.
• At-risk subgroups: Not established in humans.

Regulatory status

Not addressed in either current US label.

Population evidence

None at Tier A in humans. Tier B mechanistic evidence only, all using amantadine directly: Quarato et al. 2014 (Biochem Pharmacol), a hepatocyte cell-culture model of hepatitis-C-virus-protein-induced mitochondrial dysfunction and oxidative stress, found amantadine protective; Ocal et al. 2022 (Mol Neurobiol), a hypoxia model, found amantadine attenuated hypoxia-induced mitochondrial oxidative neurotoxicity, apoptosis, and inflammation via inhibition of TRPM2/TRPV4 channels; Bindal et al. 2026 (Medicina), rat traumatic brain injury, found amantadine modulated the HIF-1a/BNIP3L/HMGB1 axis (BNIP3L is a mitophagy-linked protein), reducing secondary oxidative and inflammatory injury.

Mechanism

Named at Tier B. NMDA-receptor channel blockade limiting excitotoxic calcium influx is the proposed upstream event in the traumatic-brain-injury and hypoxia models; the hepatitis-C-protein model implicates a separate, virus-protein-specific mitochondrial-toxicity pathway that amantadine appears to interrupt, a mechanism not obviously generalizable to Parkinson's disease.

Counter-evidence held on record

No source located contradicts the protective direction reported; the limitation is that all evidence is cell or animal, in injury or viral-toxicity models distinct from amantadine's primary indication, not a contradicting result. This is animal and cell mechanistic evidence only, using acute-injury or viral-toxicity models, and must not be read as amantadine protecting or damaging human mitochondria during ordinary Parkinson's disease treatment. No supplement or dosing action follows from this entry.

Limits on what this shows

• Key negative/null findings: No source located measured oxidative-stress markers in amantadine-treated Parkinson's disease patients on routine outpatient dosing without acute injury; the evidence base is entirely from acute-injury models (traumatic brain injury, spinal cord injury, hypoxia, one renal-inflammation model), so extrapolation to the drug's primary indication is explicitly not established.
• At-risk subgroups: Not applicable in the deficiency sense; this is a protective finding. The population in which it has been studied is acute traumatic brain injury.

Regulatory status

Not addressed in either current US label; established in the neurotrauma and injury-model literature as a treatment-associated biochemical effect.

Population evidence

Saniova et al. 2006 (Cell Mol Neurobiol), 32 patients with closed traumatic brain injury (mean age about 41), an amantadine-treated subgroup (n=18) compared with a control subgroup (n=14): malondialdehyde (a lipid-peroxidation marker) fell and beta-carotene (an antioxidant) rose significantly over 7 days in the amantadine subgroup, alongside lower mortality (5.5% versus 42.9%) and better outcome Glasgow Coma Scale scores; this is a small clinical study and the degree to which group assignment was randomized could not be confirmed from the material retrieved this session. Supporting Tier B animal/cell evidence, all amantadine-specific: Lievykh et al. 2024 (Neuroscience Applied) and Semenenko et al. 2019/2020 (Clinical and Experimental Pathology), both in rats with traumatic brain injury, reduced markers of carbonyl-oxidative stress in brain tissue; Mata-Bermudez et al. 2021 (Eur J Pain), rat spinal cord injury, reduced oxidative stress and hypersensitivity attributed specifically to NMDA-receptor antagonism; Ocal et al. 2022 (Mol Neurobiol), hypoxia model, attenuated mitochondrial oxidative neurotoxicity via inhibition of TRPM2/TRPV4 channels; Bindal et al. 2026 (Medicina), rat traumatic brain injury, reduced oxidative and inflammatory injury via the HIF-1a/BNIP3L/HMGB1 axis; Kosar et al. 2026 (Basic Clin Pharmacol Toxicol), a renal (not brain) inflammation/oxidative-stress model, also found a protective, oxidative-stress-reducing effect.

Mechanism

Named. Amantadine is an uncompetitive NMDA-receptor channel blocker; by limiting glutamate-driven calcium influx during acute tissue injury, it is proposed to reduce excitotoxicity-driven reactive-oxygen generation downstream. This is the drug's own channel-blocking pharmacology acting in an injury context, not a nutrient the drug consumes or spares.

Counter-evidence held on record

No source located contradicts the direction of this finding; the main limitation is scale (one small clinical study) and population specificity (acute injury, not routine Parkinson's dosing), not a competing result. This is a protective, redox-chemistry finding tied to amantadine's own mechanism in acute injury, not evidence that patients on amantadine need antioxidant supplementation, and not evidence that oxidative stress is a risk to manage in routine outpatient dosing. No dose of any antioxidant nutrient is recommended on the basis of this entry.

Limits on what this shows

• Why no grade: Multiple Crossref bibliographic searches combining amantadine with copper, ceruloplasmin, zinc, trace elements, and Wilson's-disease-adjacent terms were run across several differently worded queries. The only amantadine-and-copper results that came back were synthetic inorganic-chemistry papers using amantadine purely as a ligand scaffold to build copper(II) coordination complexes for antibacterial, anticancer, or catalytic purposes (for example, copper-Schiff-base complexes derived from amantadine, and a copper-BODIPY sensor that happens to use amantadine as a linker); none of these study amantadine's effect on the body's copper status and all were excluded as biologically irrelevant. No serum, ceruloplasmin, or tissue copper study in amantadine-treated humans or animals was found. A later, dedicated research pass reran these searches directly against PubMed's search-listing and abstract pages rather than Crossref metadata alone, using phrasings including "amantadine copper," "amantadine trace elements," and "amantadine zinc," and confirmed the same result: aside from the ligand-chemistry papers already excluded, the only new amantadine-and-copper hit was a 2024 case report (Suhas et al., National Medical Journal of India) of amantadine-induced psychosis in a patient with Wilson disease, a pre-existing copper-metabolism disorder; the case documents amantadine's own known dopaminergic, psychosis-inducing side effect occurring in a patient who happens to have a copper-metabolism disorder, not a mechanism by which amantadine affects copper status, and is excluded on that basis. A planned parallel check for a defensible NMDA-antagonist class extrapolation (memantine and copper) could not be completed before this session's fetch tooling was cut off mid-pass by an organization-level usage limit; that sub-check should be re-run in a future revision before this gap is treated as fully settled on the class-extrapolation question specifically. Assessment: most likely a genuine literature gap for this drug specifically (amantadine's renal, non-metabolized clearance gives no obvious copper-handling mechanism to begin with), now checked directly against PubMed abstracts rather than Crossref metadata alone, though the incomplete memantine sub-check means this is not yet fully exhaustive.

Limits on what this shows

• Why no grade: Crossref bibliographic searches combining amantadine with iron, ferritin, transferrin, serum iron, and hepcidin were run across several phrasings and returned no amantadine-specific results at all in the iron/ferritin/hepcidin-focused queries; one earlier, separately worded search surfaced a 2001 paper on phlebotomy plus amantadine in interferon-non-responder hepatitis-C patients with pre-existing serum iron overload, examined and excluded because the iron overload there is a feature of the hepatitis-C treatment protocol (interferon plus phlebotomy) that amantadine happened to be co-administered alongside, not a mechanism by which amantadine itself affects iron status. No serum iron, ferritin, or transferrin study specifically measuring amantadine's own effect was located. A later, dedicated research pass reran these searches directly against PubMed's search-listing and abstract pages rather than Crossref metadata alone and confirmed the same result. One new hit surfaced: a 2024 case series (Song et al., Journal of Huntington's Disease) on delusional infestation in Huntington's disease, in which one patient's psychotic symptoms improved with risperidone, iron supplementation, and amantadine discontinuation given concurrently; this is examined and excluded as confounded, amantadine was most likely discontinued for its own known dopaminergic, psychosis-inducing side effect, the same mechanism documented elsewhere in this dossier, rather than for an iron-related reason, and iron deficiency is independently associated with delusional infestation in the psychiatric literature regardless of amantadine exposure. A planned parallel check for an NMDA-antagonist class extrapolation (memantine and iron) could not be completed before this session's fetch tooling was cut off mid-pass by an organization-level usage limit; that sub-check should be re-run in a future revision. Assessment: most likely a genuine literature gap, consistent with amantadine's PK prescreen showing no absorption-interference or GI mechanism that would plausibly affect iron uptake, now checked directly against PubMed abstracts rather than Crossref metadata alone, though the incomplete memantine sub-check means this is not yet fully exhaustive.

Limits on what this shows

• Key negative/null findings: The one study that measured amantadine directly, Bedarf et al. 2017, found no significant taxa-level or functional microbiome difference associated with amantadine use (grouped with other dopaminergic and MAO-B-inhibitor therapy) in humans. The memantine finding itself is bounded: ex vivo, high-concentration only, limited to a single bacterial species (E. coli biofilm), and did not extend to general fecal bacterial viability or to any of the three acetylcholinesterase inhibitors tested in the same study.
• At-risk subgroups: None established for amantadine specifically.

Regulatory status

Not addressed in either current US label.

Population evidence

Bedarf et al. 2017 (Genome Medicine), a fecal shotgun metagenomic comparison of 31 early-stage, L-DOPA-naive Parkinson's disease patients against 28 age-matched controls: a medication-subgroup analysis covering about 90% of the PD cohort found that intake of an MAO-B inhibitor, amantadine, or a dopamine agonist, grouped together rather than analyzed as separate subgroups, had no significant effect on bacterial taxa abundance or microbial functional pathways; amantadine was in the cohort by name but not isolated as its own arm. Tier C class-level evidence, using memantine rather than amantadine: Nguyen et al. 2021 (Int J Mol Sci), an ex vivo mouse study testing memantine alongside three acetylcholinesterase inhibitors on fecal bacterial viability, biofilm formation, colonic propulsion, and enteric-neuron properties, found no direct effect of any tested drug on general fecal bacterial viability; only a high concentration of memantine reduced E. coli biofilm formation by about 10 percent (p = 0.026) and elevated calcium influx in enteric neurons, with no effect on enteric-neuron viability or neurite outgrowth. Memantine and amantadine are both aminoadamantane, uncompetitive NMDA-receptor channel blockers, the same class relationship used elsewhere in this dossier for the oxidative-stress and mitochondrial entries, though amantadine's NMDA-channel affinity is weaker than memantine's.

Mechanism

Proposed only at Tier C, via memantine: NMDA-receptor and calcium-channel activity in enteric neurons, alongside a modest direct antibiofilm action against E. coli at a high local concentration. Not established for amantadine itself, and amantadine's comparatively weak NMDA-channel affinity is a further reason this extrapolation is bounded rather than confirmed.

Counter-evidence held on record

The direct amantadine data (Bedarf et al. 2017) is a null finding, which weighs against extrapolating even the modest memantine result to amantadine's own effect on the gut microbiome at ordinary oral dosing. This is a Tier C class extrapolation resting on a different drug, memantine, tested ex vivo at a high concentration against one bacterial species, not a demonstrated amantadine effect on the human gut microbiome; the one study that tested amantadine directly found no effect. No probiotic, prebiotic, or microbiome-directed supplement action follows from this entry.

Limits on what this shows

• Key negative/null findings: Neither current FDA label lists anemia, hemolysis, or reduced hemoglobin among amantadine's adverse reactions at any frequency tier, a meaningful null finding at Tier A that bounds this entry to yellow; this contrasts with a drug like carbidopa-levodopa, whose label does list hemolytic anemia.
• At-risk subgroups: None established in humans; the source is an in vitro study only.

Regulatory status

Not addressed in either current US label. Neither the Symmetrel nor the Gocovri label lists anemia or hemolysis among amantadine's adverse reactions; a dedicated drugs.com side-effects reference confirms the same absence.

Population evidence

Foller et al. 2008 (Eur J Pharmacol), human erythrocytes exposed in vitro to amantadine at 0.2 to 1 microgram/mL, concentrations overlapping the drug's own labeled therapeutic plasma range: amantadine increased intracellular calcium, triggered annexin V binding (indicating phosphatidylserine exposure, a marker of eryptosis), and increased forward scatter (reflecting cell shrinkage); the annexin V response was virtually abolished in the absence of extracellular calcium, confirming a calcium-dependent mechanism. No human in vivo or clinical hematologic study of amantadine and red-cell survival was located.

Mechanism

Named. Amantadine-induced calcium entry into erythrocytes activates the eryptosis pathway (phosphatidylserine externalization, cell shrinkage), the same general pathway other drugs and endogenous stressors use to trigger accelerated red-cell clearance; the specific molecular target on the erythrocyte membrane was not identified in the abstract retrieved.

Counter-evidence held on record

The absence of any anemia or hemolysis signal across two current FDA labels for this drug is real counter-evidence bounding this entry; it does not disprove the in vitro mechanism, but it means the mechanism has not been shown to produce a clinically detectable effect on oxygen-carrying capacity in humans taking amantadine at labeled doses. This is a cell-biology mechanism from a single in vitro study, not a demonstrated anemia risk. It is not a reason to supplement iron or B12 in anticipation of it, and any anemia that does occur in a patient on amantadine warrants standard hematologic workup rather than assumption that this mechanism is the cause.

Limits on what this shows

• Key negative/null findings: No later replication or contradiction of this finding, in rats or any other species, was located despite a genuinely broad search; a 50-year gap with no follow-up study is itself a reason for caution about how much weight this single result carries.
• At-risk subgroups: None established.

Regulatory status

Not addressed in either current US label.

Population evidence

Velkov 1974 (Experientia, now Cellular and Molecular Life Sciences), rats given amantadine hydrochloride: brainstem Na-K-ATPase activity was increased; the paper's title also references ATP content in brain and blood, but only the ATPase-activity finding and its proposed membrane-permeability interpretation could be retrieved from the sources reachable this session, the article predates the routine publication of structured abstracts and the full text sits behind a subscription paywall that a direct publisher-page check could not get past. This is disclosed as a genuine, drug-specific, cohort-tested primary source with a confirmed partial finding, not a fully characterized one.

Mechanism

Proposed by the study's authors only: altered neuronal membrane permeability affecting an ATP-dependent ion pump. This is a plausible but unreplicated mechanistic claim, not independently confirmed elsewhere in the sources located.

Counter-evidence held on record

None located in either direction; the limitation is a single, old, small, unreplicated study with an interpretation (increased ATPase activity) that does not straightforwardly map onto "ATP production is depleted" or "ATP production is enhanced." This is 1970s-era animal mechanistic evidence only and should not be read as amantadine either draining or boosting cellular energy production in humans. No supplement, dose, or monitoring action follows from this entry.